Successful Treatment of γ-Heavy-Chain Disease with Rituximab and Fludarabine
Acta Haematologica, 08/10/2012
Inoue D et al. – The authors performed only a single course of immunochemotherapy (rituximab and fludarabine) in view of severely impaired hematopoiesis, which resulted in marked reduction of lymphoma cells and improvement of hematopoiesis. This report suggests the efficacy of rituximab plus fludarabine therapy for lymphoplasmacytic lymphoma (LPL)–associated γ–heavy–chain disease (γ–HCD).